Risk of Progression of Cervical Intraepithelial Neoplasia Grade 2 by HPV Vaccination Status

Publikation: KonferencebidragPosterForskningpeer review

Standard

Risk of Progression of Cervical Intraepithelial Neoplasia Grade 2 by HPV Vaccination Status. / Krog, Louise; Lycke, Kathrine Dyhr; Kahlert, Johnny et al.

2022. Poster session præsenteret ved Kongres for Medicinsk Studenterforskning 2022, Sandbjerg, Danmark.

Publikation: KonferencebidragPosterForskningpeer review

Harvard

Krog, L, Lycke, KD, Kahlert, J, Jensen, PT, Rositch, A & Hammer, A 2022, 'Risk of Progression of Cervical Intraepithelial Neoplasia Grade 2 by HPV Vaccination Status', Kongres for Medicinsk Studenterforskning 2022, Sandbjerg, Danmark, 10/03/2022 - 13/03/2022.

APA

Krog, L., Lycke, K. D., Kahlert, J., Jensen, P. T., Rositch, A., & Hammer, A. (2022). Risk of Progression of Cervical Intraepithelial Neoplasia Grade 2 by HPV Vaccination Status. Poster session præsenteret ved Kongres for Medicinsk Studenterforskning 2022, Sandbjerg, Danmark.

CBE

Krog L, Lycke KD, Kahlert J, Jensen PT, Rositch A, Hammer A. 2022. Risk of Progression of Cervical Intraepithelial Neoplasia Grade 2 by HPV Vaccination Status. Poster session præsenteret ved Kongres for Medicinsk Studenterforskning 2022, Sandbjerg, Danmark.

MLA

Krog, Louise et al. Risk of Progression of Cervical Intraepithelial Neoplasia Grade 2 by HPV Vaccination Status. Kongres for Medicinsk Studenterforskning 2022, 10 mar. 2022, Sandbjerg, Danmark, Poster, 2022.

Vancouver

Krog L, Lycke KD, Kahlert J, Jensen PT, Rositch A, Hammer A. Risk of Progression of Cervical Intraepithelial Neoplasia Grade 2 by HPV Vaccination Status. 2022. Poster session præsenteret ved Kongres for Medicinsk Studenterforskning 2022, Sandbjerg, Danmark.

Author

Krog, Louise ; Lycke, Kathrine Dyhr ; Kahlert, Johnny et al. / Risk of Progression of Cervical Intraepithelial Neoplasia Grade 2 by HPV Vaccination Status. Poster session præsenteret ved Kongres for Medicinsk Studenterforskning 2022, Sandbjerg, Danmark.

Bibtex

@conference{051d551d4da84f06a97a599d5c38f8a4,
title = "Risk of Progression of Cervical Intraepithelial Neoplasia Grade 2 by HPV Vaccination Status",
abstract = "Background: HPV infection can lead to cervical precancer (cervical intraepithelial neoplasia [CIN], graded as CIN1 [mild], CIN2 [moderate], and CIN3 [severe]) and cancer. Historically, CIN2 was surgically removed, but as this is associated with preterm birth, fertile women are now recommended active surveillance. However, identification of women at risk of progression is needed. HPV vaccination protects against cervical cancer, but it is unknown if HPV vaccination status can be used to risk stratify CIN2.Materials and methods: We will conduct a nationwide population-based cohort study using data from Danish registers. We will identify women with an incident CIN2 diagnosis during 2010-2020. Information on exposure (HPV vaccination) will be retrieved, as will all subsequent cervical samples to determine the outcome (regression, persistence, or progression of CIN2). We will estimate the risk of CIN2 progression among HPV-vaccinated vs. unvaccinated women adjusting for socio-economic status and other important covariates.Results: The project is currently ongoing, and no results are obtained yet. Cox regression will be applied to estimate the hazard of progression to CIN3 or cancer by HPV vaccination status (vaccinated vs. unvaccinated). Results will be stratified by age at CIN2 diagnosis, birth year, year of CIN2 diagnosis, years since vaccination, age at vaccination, number of vaccine doses, and type of vaccine.Conclusion: We expect our results will contribute with knowledge on whether HPV vaccination status can be used to identify risk of progression of CIN2. This will provide clinicians with important information that may be useful in clinical counselling and shared decision-making.",
author = "Louise Krog and Lycke, {Kathrine Dyhr} and Johnny Kahlert and Jensen, {Pernille Tine} and Anne Rositch and Anne Hammer",
year = "2022",
month = mar,
language = "English",
note = "null ; Conference date: 10-03-2022 Through 13-03-2022",

}

RIS

TY - CONF

T1 - Risk of Progression of Cervical Intraepithelial Neoplasia Grade 2 by HPV Vaccination Status

AU - Krog, Louise

AU - Lycke, Kathrine Dyhr

AU - Kahlert, Johnny

AU - Jensen, Pernille Tine

AU - Rositch, Anne

AU - Hammer, Anne

PY - 2022/3

Y1 - 2022/3

N2 - Background: HPV infection can lead to cervical precancer (cervical intraepithelial neoplasia [CIN], graded as CIN1 [mild], CIN2 [moderate], and CIN3 [severe]) and cancer. Historically, CIN2 was surgically removed, but as this is associated with preterm birth, fertile women are now recommended active surveillance. However, identification of women at risk of progression is needed. HPV vaccination protects against cervical cancer, but it is unknown if HPV vaccination status can be used to risk stratify CIN2.Materials and methods: We will conduct a nationwide population-based cohort study using data from Danish registers. We will identify women with an incident CIN2 diagnosis during 2010-2020. Information on exposure (HPV vaccination) will be retrieved, as will all subsequent cervical samples to determine the outcome (regression, persistence, or progression of CIN2). We will estimate the risk of CIN2 progression among HPV-vaccinated vs. unvaccinated women adjusting for socio-economic status and other important covariates.Results: The project is currently ongoing, and no results are obtained yet. Cox regression will be applied to estimate the hazard of progression to CIN3 or cancer by HPV vaccination status (vaccinated vs. unvaccinated). Results will be stratified by age at CIN2 diagnosis, birth year, year of CIN2 diagnosis, years since vaccination, age at vaccination, number of vaccine doses, and type of vaccine.Conclusion: We expect our results will contribute with knowledge on whether HPV vaccination status can be used to identify risk of progression of CIN2. This will provide clinicians with important information that may be useful in clinical counselling and shared decision-making.

AB - Background: HPV infection can lead to cervical precancer (cervical intraepithelial neoplasia [CIN], graded as CIN1 [mild], CIN2 [moderate], and CIN3 [severe]) and cancer. Historically, CIN2 was surgically removed, but as this is associated with preterm birth, fertile women are now recommended active surveillance. However, identification of women at risk of progression is needed. HPV vaccination protects against cervical cancer, but it is unknown if HPV vaccination status can be used to risk stratify CIN2.Materials and methods: We will conduct a nationwide population-based cohort study using data from Danish registers. We will identify women with an incident CIN2 diagnosis during 2010-2020. Information on exposure (HPV vaccination) will be retrieved, as will all subsequent cervical samples to determine the outcome (regression, persistence, or progression of CIN2). We will estimate the risk of CIN2 progression among HPV-vaccinated vs. unvaccinated women adjusting for socio-economic status and other important covariates.Results: The project is currently ongoing, and no results are obtained yet. Cox regression will be applied to estimate the hazard of progression to CIN3 or cancer by HPV vaccination status (vaccinated vs. unvaccinated). Results will be stratified by age at CIN2 diagnosis, birth year, year of CIN2 diagnosis, years since vaccination, age at vaccination, number of vaccine doses, and type of vaccine.Conclusion: We expect our results will contribute with knowledge on whether HPV vaccination status can be used to identify risk of progression of CIN2. This will provide clinicians with important information that may be useful in clinical counselling and shared decision-making.

M3 - Poster

Y2 - 10 March 2022 through 13 March 2022

ER -